Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. TSLA
7. DPZ
8. NVDA
9. PRIM
10. META

Go back to Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
(NASDAQ: MNPR) Delayed: 77.61 +8.95 (13.04%)
Previous Close $68.66    52 Week High $ 
Open $68.21    52 Week Low $ 
Day High $78.00    P/E N/A 
Day Low $68.21    EPS $ 
Volume 100,265